A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 18, 1998, Pages 2545-2548

  Papot, Sébastien ^a   Combaud, Damien ^a   Gesson, Jean Pierre ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; DOXORUBICIN; DOXORUBICIN DERIVATIVE; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; PRODRUG; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DIAGNOSTIC VALUE; DRUG STABILITY; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROPHILICITY; MOLECULAR RECOGNITION; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; GLUCURONATES; GLUCURONIDASE; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PRODRUGS;

EID: 0032558480     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00454-5     Document Type: Article

References (15)

1. 1. Jacquesy, J.-C.; Gesson, J.-P.; Monneret, C.; Mondon, M., Renoux, B.; Florent, J.-C.; Koch, M.; Tillequin, F.; Sedlacek, H.H.; Gerken, M.; Kolar, C.; Gaudel, G.; Bosslet, K.; Czech, J.; Hoffmann, D.; Seeman, G.; Eur. Pat. Appl. 1992, EP 511,917, Chem Abstr. 1994, 120, 271070s.
2. 2. ADEPT : Antibody Directed Enzyme Prodrug Therapy. a) Bagshawe, K.D. Drug Dev. Res. 1995, 34, 220-230.
3. b) Niculescu-Duvaz, I.; Springer, C.J. Curr. Med. Chem. 1995, 2, 687-706.
4. c) Melton, R.G.; Sherwood, R.F. J. Natl. Cancer Inst. 1996, 21, 153-165.
5. 3. PMT : Prodrug Monotherapy. Bosslet, K.; Czech, J.; Hoffmann, D., Tumor Targeting, 1995, 1, 45-50.
6. 4. Bosslet, K.; Czech, J.; Hoffmann, D., Cancer Res., 1994, 54, 2151-2159.
7. 5. a) Haisma, H. J.; Boven, E.; van Muijen, M.; De Jong, J.; van der Vijgh, W. J.; Pinedo, H. M. Br. J. Cancer, 1992, 66, 474-478.
8. b) Houba, P. H. J.; Leenders, G. G.; Boven, E.; Scheeren, J. W.; Pinedo, H. M.; Haisma, H. J. Biochemical Pharmacology, 1996, 52, 455-463.
9. 6. Schmidt, F.; Florent, J. C.; Monneret, C.; Straub, R.; Czech, J.; Gerken, M.; Bosslet, K. Bioorg. Med. Chem. Lett., 1997, 7, 1071-1076.
10. 7. Fisher, R., Acros Organics Acta, 1996, 2, 1-5.
11. 13C NMR and HRMS.
12. 9. Lubineau, A.; Queneau, Y. Tetrahedron, 1989, 45, 6697-6712.
13. 10. Gupta, R.C., Harland, P.A.; Stoodley, J.-F. Tetrahedron, 1984, 40, 4657-4668.
14. 11. Ghosh, A. K., Farquhar D. Tetrahedron Lett., 1997, 38, 8795-8798.
15. 12. HPLC conditions; C-18 reverse phase column: LiChroCART 125-4 and pre-cotumn (LiChrospher® 100 RP-18 (5 μm), UV detection (λ 254 nm); mobile phase (acetonitrile/0,02M phosphate buffer, 15/85 to 75/35, pH 3, 1 mL/min). Retention time: 10: 14.25 min; 11: 13.1 min and DOX: 10.0 min.